http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7662792-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5adf46b1e66719c8aef4bd5610dae03f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
filingDate 2002-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2010-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9824ed00d5bcf26bfaf71be4bc627005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0becbee7971744cbc930289073934921
publicationDate 2010-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-7662792-B2
titleOfInvention Modulation of Fas and FasL expression
abstract A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG) n , (GT) n , a(GT) n b, a(GA) n b, and a(GC) n b, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009087456-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8609108-B2
priorityDate 1999-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9720924-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6150339-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9408053-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5643890-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6316190-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9623508-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6015710-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4791101-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7125858-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9417086-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6197
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394009
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445127
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226933920
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66751919
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135968306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414426

Total number of triples: 48.